Biomarker Study: Impact of Single Doses of LY2979165 and LY2140023 on the Ketamine-Challenge Pharmacological MRI Assay in Healthy Male Subjects.
Phase of Trial: Phase I
Latest Information Update: 01 Aug 2013
At a glance
- Drugs MP 101 Mediti Pharma (Primary) ; Pomaglumetad methionil (Primary) ; Ketamine
- Indications Bipolar disorders; Schizophrenia
- Focus Adverse reactions; Biomarker; Pharmacodynamics
- 29 Aug 2012 Status changed from recruiting to discontinued, according to an Eli Lilly media release.
- 02 Jul 2012 Planned end date changed from 1 Mar 2013 to 1 Jun 2013 as reported by ClinicalTrials.gov.
- 02 May 2012 Planned end date changed from 1 Jan 2013 to 1 Mar 2013 as reported by ClinicalTrials.gov.